581. |
582. |
583. |
584. |
585. |
586. |
587. Paratesticular adenocarcinoma : unusual presentation of metastasis of pancreatic cancerJanja Ocvirk, Boštjan Šeruga, 2007, drugi znanstveni članki Povzetek: Background. Metastatic paratesticular adenocarcinoma from the pancreatic cancer is very rare. To our knowledge, there are less than 20 cases published in the literature. Case report. We experienced a case of paratesticular adenocarcinoma from the primary pancreatic cancer. A 42-year-old man was presented with locoregionally advanced carcinoma of the tail of the pancreas with intraoperatively found liver metastases and with a tumour in the right hemi-scrotum. Ultrasound of the scrotum revealed a paratesticular tumour. A fine needle aspiration biopsy (FNAB) confirmed a poorly differentiated adenocarcinoma and it was in concordance with the diagnosis of the primary tumour. The patient started treatment with chemotherapy with gemcitabine. Unfortunately, he progressed one month later and the treatment was discontinued. Conclusions. Outcome in the adenocarcinoma of the pancreas is dismal. The only possible treatment option for metastatic disease is systemic therapy but the results are disappointing, as in the present case.
Objavljeno v DiRROS: 19.02.2024; Ogledov: 375; Prenosov: 88
 Celotno besedilo (78,71 KB) |
588. Tumor vaccinesMojca Frank Bertoncelj, Alojz Ihan, 2006, pregledni znanstveni članek Povzetek: Tumor vaccines have several potential advantages over standard anticancer regirrcents. They represent highly specific anticancer therapy. Inducing tumor-specific memory T-lymphocytes, they have potential for long-lived antitumor effects. However, clinical trials, in which cancer patients were vaccinated with tccmor aaccines, have been so far mainly disappointing. There are many reasons for the inefficiency of tumor vaccines. Most cancer antigens are normal self-molecules to which imrrtune tolerance exists. That is why the population of tumor-specific lymphocytes is represented by a small number of low-affinity T-lymphocytes that induce weak antitumor immune response. Simultaneously, tumors evolve many mechanisms to actively evade immune system,what makes them poorly immunogenic or even tolerogenic. Novel irrtmunotherapeutic strategies are directed toward breaking immune tolerance to tumor antigens, enhancing immunogenicity of tumor vaccines and overcoming mechanisms of tumor escape. There are several approaches, unfortunately, all of them still far away from an ideal tumor vaccine that would reject a tumor. Difficulties in the activation of antitumor immune response by tumor vaccines have led to the development of alternative immunotherapeutic strategies that directly focus on effector mechanisms of immune system (adoptive tumor-specific T-lymphocyte transfer and tumor specific monoclonal antibodies).
Objavljeno v DiRROS: 15.02.2024; Ogledov: 409; Prenosov: 92
Celotno besedilo (115,82 KB) |
589. Electrochemotherapy of tumoursGregor Serša, Maja Čemažar, Damijan Miklavčič, Zvonimir Rudolf, 2006, pregledni znanstveni članek Povzetek: Electroehemotherapy consists of chemotherapy followed by local application of electrie pulses to the tumour to increase drug delivery into cells. Drug uptake can be inereased by electroporation for only those drugs whose transport through the plasma membrane is impeded. Among many drugs that have been tested so far, only bleomycin and cisplatin found their way from preclinical testing to clinical trials. In vitro studies demonstrated several fold inerease of their cytotoxicity after electroporation of cells. In vivo, electroporation of tumours after local or systemic administration of either ofthe drugs, i.e. electrochemotherapy, proved to be an effective antitumour treatment. In preclinical studies on several tumour models, electrochemotherapy either with bleomycin or cisplatin was elaborated and parameters for effective local tumour control were determined. In veterinary medicine, electrochemotherapy also proved to be effective in the treatment of primary tumours in cats, dogs and horses. In human clinical studies, electrochemotherapy was performed on the patients with progressive disease andaccessible tumour nodules of different malignancies. All clinical studies demonstrated that electrochemotherapy is an effective treatment for local tumour control in cancer patients.
Objavljeno v DiRROS: 15.02.2024; Ogledov: 534; Prenosov: 113
Celotno besedilo (225,92 KB) |
590. |
